NovaBay Pharmaceuticals, Inc. (NBY)

USD 0.51

(4.08%)

Long Term Debt Summary of NovaBay Pharmaceuticals, Inc.

  • NovaBay Pharmaceuticals, Inc.'s latest annual long term debt in 2023 was 1.1 Million USD , down -30.23% from previous year.
  • NovaBay Pharmaceuticals, Inc.'s latest quarterly long term debt in 2024 Q2 was 932 Thousand USD , down 0.0% from previous quarter.
  • NovaBay Pharmaceuticals, Inc. reported annual long term debt of 1.58 Million USD in 2022, up 545.53% from previous year.
  • NovaBay Pharmaceuticals, Inc. reported annual long term debt of 246 Thousand USD in 2021, up 182.76% from previous year.
  • NovaBay Pharmaceuticals, Inc. reported quarterly long term debt of 1.04 Million USD for 2024 Q1, down 0.0% from previous quarter.
  • NovaBay Pharmaceuticals, Inc. reported quarterly long term debt of 1.51 Million USD for 2023 Q1, down -4.79% from previous quarter.

Annual Long Term Debt Chart of NovaBay Pharmaceuticals, Inc. (2023 - 2003)

Created with Highcharts 11.1.0YearsLong Term Debt20042006200820102012201420162018202020220 USD500000 USD1000000 USD1500000 USD2000000 USD

Historical Annual Long Term Debt of NovaBay Pharmaceuticals, Inc. (2023 - 2003)

Year Long Term Debt Long Term Debt Growth
2023 1.1 Million USD -30.23%
2022 1.58 Million USD 545.53%
2021 246 Thousand USD 182.76%
2020 87 Thousand USD -82.77%
2019 505 Thousand USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD -100.0%
2015 1.65 Million USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD -100.0%
2009 106 Thousand USD -77.78%
2008 477 Thousand USD -12.64%
2007 546 Thousand USD 0.0%
2006 - USD 0.0%
2005 - USD 0.0%
2003 - USD 0.0%

Peer Long Term Debt Comparison of NovaBay Pharmaceuticals, Inc.

Name Long Term Debt Long Term Debt Difference
AIM ImmunoTech Inc. 495 Thousand USD -123.838%
Ampio Pharmaceuticals, Inc. - USD -Infinity%
Armata Pharmaceuticals, Inc. 82.3 Million USD 98.654%
Actinium Pharmaceuticals, Inc. 1.57 Million USD 29.517%
Azitra, Inc. 563.69 Thousand USD -96.561%
Can-Fite BioPharma Ltd. 13 Thousand USD -8423.077%
Chromocell Therapeutics Corporation - USD -Infinity%
Calidi Biotherapeutics, Inc. 2.06 Million USD 46.214%
CEL-SCI Corporation 11.6 Million USD 90.45%
iBio, Inc. 3.5 Million USD 68.406%
Lineage Cell Therapeutics, Inc. 2.07 Million USD 46.473%
MAIA Biotechnology, Inc. - USD -Infinity%
Matinas BioPharma Holdings, Inc. 2.89 Million USD 61.727%
Navidea Biopharmaceuticals, Inc. 1.87 Million USD 40.803%
NanoViricides, Inc. - USD -Infinity%
Oragenics, Inc. - USD -Infinity%
BiomX Inc. 5.4 Million USD 79.489%
BiomX Inc. 5.4 Million USD 79.489%
Protalix BioTherapeutics, Inc. 4.62 Million USD 76.023%
Palatin Technologies, Inc. 163.78 Thousand USD -576.509%
Scorpius Holdings, Inc. 12.61 Million USD 91.216%
Theriva Biologics, Inc. 162 Thousand USD -583.951%